Reportstack has announced a new market research report on the Global Ankylosing Spondylitis Market 2015-2019, which is expected to grow at a CAGR of 5.05 percent during the period 2014-2019.
Current treatment options cannot cure the disease completely, and the drugs have a low safety profile, resulting in a rate high mortality. Therefore, drugs that can cause disease remission in patients and have a high safety profile are expected to drive the growth of the market. Moreover, increase in patient assistance programs initiated by various governmental and non-governmental organizations and major vendors to support patients suffering from ankylosing spondylitis propel the growth of the Global Ankylosing Spondylitis market.
“The Ankylosing Spondylitis market in emerging countries is expected to grow at a rapid pace owing to an increase in patient population and public awareness about ankylosing spondylitis,”.
“Drug manufacturers focus on these countries with the motive of launching new products and penetrating into these markets.”
Key Market Drivers
Presence of High Unmet Needs
Increase in Patient Assistance Programs
Expected Launch of Pipeline Drugs
Key Market Trends
Dominance of Market by Biologics
Growing Public Awareness
Growing Focus on Emerging Markets
Key Market Vendors
Janssen Pharmaceuticals Inc.
Merck & Co. Inc.
To define the market circumstances in the next 3-4 years, the analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
Complete report available @ Global Ankylosing Spondylitis Market 2015-2019.